Morgan Stanley Novo Cure LTD Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Novo Cure LTD stock. As of the latest transaction made, Morgan Stanley holds 608,126 shares of NVCR stock, worth $12.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

608,126

Previous 670,121 9.25%

Holding current value

$12.8 Million

Previous $10.5 Million 73.04%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$14.54 - $33.41 $901,407 - $2.07 Million	-61,995 Reduced 9.25%	608,126 $18.1 Million
Q3 2024 Nov 14, 2024	SELL	$15.61 - $23.34 $2.13 Million - $3.18 Million	-136,403 Reduced 16.91%	670,121 $10.5 Million
Q2 2024 Oct 17, 2024	SELL	$11.83 - $24.05 $11.2 Million - $22.9 Million	-950,115 Reduced 54.09%	806,524 $13.8 Million
Q2 2024 Aug 14, 2024	SELL	$11.83 - $24.05 $11.2 Million - $22.9 Million	-950,115 Reduced 54.09%	806,524 $13.8 Million
Q1 2024 Oct 17, 2024	BUY	$12.42 - $17.29 $11.8 Million - $16.4 Million	950,115 Added 117.8%	1,756,639 $27.5 Million
Q1 2024 Aug 16, 2024	BUY	$12.42 - $17.29 $4.2 Million - $5.85 Million	338,155 Added 23.84%	1,756,639 $27.5 Million
Q1 2024 May 15, 2024	BUY	$12.42 - $17.29 $4.2 Million - $5.85 Million	338,155 Added 23.84%	1,756,639 $27.5 Million
Q4 2023 Aug 16, 2024	BUY	$11.13 - $15.78 $6.81 Million - $9.66 Million	611,960 Added 75.88%	1,418,484 $21.2 Million
Q4 2023 Feb 13, 2024	BUY	$11.13 - $15.78 $3.66 Million - $5.19 Million	328,864 Added 30.18%	1,418,484 $21.2 Million
Q3 2023 Nov 15, 2023	BUY	$16.15 - $42.35 $4.51 Million - $11.8 Million	279,070 Added 34.43%	1,089,620 $17.6 Million
Q2 2023 Aug 14, 2023	BUY	$40.29 - $82.51 $13.2 Million - $27.1 Million	327,956 Added 67.96%	810,550 $33.6 Million
Q1 2023 May 15, 2023	SELL	$56.44 - $118.81 $533,358 - $1.12 Million	-9,450 Reduced 1.92%	482,594 $29 Million
Q4 2022 Feb 14, 2023	SELL	$63.98 - $85.37 $28.3 Million - $37.7 Million	-442,169 Reduced 47.33%	492,044 $36.1 Million
Q3 2022 Nov 14, 2022	SELL	$67.99 - $89.57 $6.4 Million - $8.43 Million	-94,125 Reduced 9.15%	934,213 $71 Million
Q2 2022 Oct 27, 2022	BUY	$56.6 - $89.9 $16.9 Million - $26.9 Million	298,689 Added 40.94%	1,028,338 $71.5 Million
Q2 2022 Aug 15, 2022	BUY	$56.6 - $89.9 $16.9 Million - $26.9 Million	298,689 Added 40.94%	1,028,338 $71.5 Million
Q1 2022 Oct 27, 2022	SELL	$60.15 - $84.52 $18 Million - $25.2 Million	-298,689 Reduced 29.05%	729,649 $60.5 Million
Q1 2022 May 13, 2022	SELL	$60.15 - $84.52 $5.82 Million - $8.18 Million	-96,765 Reduced 11.71%	729,649 $60.5 Million
Q4 2021 Feb 14, 2022	SELL	$75.08 - $121.99 $4.34 Million - $7.05 Million	-57,771 Reduced 6.53%	826,414 $62 Million
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $103 Million - $172 Million	884,185 New	884,185 $103 Million

Others Institutions Holding NVCR

# of Institutions

290

Shares Held

75.6M

Call Options Held

1.77M

Put Options Held

538K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.2B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account